It looks like there’s some confusion here between half year and full year numbers. Tekvest was talking about the sales and losses for just the first half of FY24, which were $10.139 million in sales and a $5.625 million loss. On the other hand, TA007 is referring to full-year projections or expected revenue, which would be higher. Both points are valid but are just looking at different timeframes.
Tekvest numbers for the half year ending Dec 2023 seem to be right, but last years larger loss was partly due to a one off cash impaiorment, which wasnt a factor this year.
CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-487
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
-0.010(4.55%) |
Mkt cap ! $48.10M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 22.5¢ | 21.0¢ | $87.21K | 406.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 400685 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 23537 | 2 |
View Market Depth
| Last trade - 16.10pm 13/08/2024 (20 minute delay) ? |
| EYE (ASX) Chart |